Sally Church, PhD
Sally helps pharma & biotech companies understand the oncology market, and focus on the right commercial opportunity for new products. She also coaches senior executives on oncology, which is a scientifically complex therapeutic area.
Recognized as an industry expert (she has appeared on CNBC and been widely quoted in the media, including NPR), Sally is considered to be one of the Top 50 women on Twitter, where as @MaverickNY she is a frequent commentator.
Sally’s widely read Pharma Strategy Blog showcases her knowledge of cancer biology and new product development. She regularly writes about scientific data presented at conferences such as ASH, EHA, AUA, EAU, AACR, ASCO & ESMO/ECCO. Since 2013 she has been the Editor of Biotech Strategy Blog.
Recently, she has additionally taken on the role of Executive Producer of the Novel Targets podcast.
With over 20 years experience in the pharmaceutical industry in the UK & United States, Sally has held executive positions in sales, marketing and new product development, and has received numerous business achievement awards. At Novartis Oncology she co-led the initial US launches of Gleevec® in CML and GIST.
Sally’s qualifications includes a PhD from Kings College London, MBA from Rutgers and a Master of Science degree in Human & Applied Physiology. A keen sportswomen who has played at national and county level in cricket and hockey, her undergraduate degree is in Sports Science. Sally has also undertaken executive education in finance at Harvard Business School.
Sally donates her spare time to charitable cancer causes and sits on the board of directors of a non-profit organization, GRACE (Global Resource for Advancing Cancer Education) which focuses primarily on lung cancer education.